Drugs / TSN222
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05842785 | Jul 2023 → Jun 2025 overdue | neoplastic disease or syndrome | Tyligand Bioscience (Shanghai) Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-02-16 | Tyligand Bioscience (Shanghai) Limited | Regulatory Tyligand Bioscience Receives Clinical Trial Clearance from U.S. FDA and China NMPA for Dual Function Immune Agonist TSN222 tyligand.com.cn ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-07-28 | Tyligand Bioscience (Shanghai) Limited | Tyligand Bioscience Announces First Patient Dosed for the Phase 1 Trial of TSN222，the Global First Dual Action Tumor Immune Agonist tyligand.com.cn ↗ |
| 2023-02-16 | Tyligand Bioscience (Shanghai) Limited | Tyligand Bioscience Receives Clinical Trial Clearance from U.S. FDA and China NMPA for Dual Function Immune Agonist TSN222 tyligand.com.cn ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSN222 | “100 microgram (μg), 200 μg, 400 μg, 800 μg, 1600 μg, and 3200 μg of TSN222 as a single agent in subjects with advanced solid tumors or lymphomas.” NCT05842785 ↗ |